Gait Patterns After Intraarticular Treatment of Patients With Osteoarthritis of the Knee
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00731289 |
Recruitment Status :
Completed
First Posted : August 8, 2008
Last Update Posted : August 8, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Osteoarthritis | Drug: hyaluronic acid Drug: triamcinolone | Phase 4 |
Osteoarthritis (OA) is the most common chronic joint disease of the aging patient. The primarily affected joints are the knee and hip. The progress of the disease has an important influence on the patient´s life, including functional and social activities, body image and emotional well being. Furthermore, socioeconomic aspects play an eminent role in the treatment of osteoarthritis in joints.
In non-operative treatment, pain reduction and improved function are the primary goals. It is important to distinguish between systemic and local therapeutic options. In the systemic treatment, palliation of pain can be achieved by simple analgetics, non- steroidal anti-inflammatory drugs and opioids. Local therapy can selectively treat the symptomatic joint. Intraarticular application of different drugs by injection can be performed. Glucocorticoids are the most commonly used intraarticular agents, which reduce pain and improve function and well being. In recent years, the intraarticular use of different hyaluronan (HA) products became more widely accepted. Hyaluronan is a physiological component of the synovial fluid and cartilage matrix. It is responsible for the viscoelastic properties of the synovial fluid. In osteoarthrotic joints, the molecular weight and the concentration of endogenous HA are decreased compared with healthy joints. This implies a reduction of the viscoelasticity of the synovial fluid. In order to restore this viscoelasticity, augment the flow of the synovial fluid, normalise the synthesis and inhibit the degradation of endogenous hyaluronan, an application of exogenous HA can be performed. The therapeutic effects and the safety of intraarticular application of HA in the treatment of OA in the knee have been demonstrated in several clinical trials. Until now there are only three studies that objectively analysed few aspects of the functional outcome after treatment with HA.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Efficacy and Safety of Intra-Articular Injections of Durolane® in the Treatment of Osteoarthritis in the Knee |
Study Start Date : | July 2003 |
Actual Primary Completion Date : | December 2005 |
Actual Study Completion Date : | December 2005 |

Arm | Intervention/treatment |
---|---|
Experimental: 1
single intraarticular injection of hyaluronan 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
|
Drug: hyaluronic acid
one intraarticular injection of hyaluronan (HA) 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
Other Name: 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) |
Active Comparator: 2
single intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)
|
Drug: triamcinolone
one intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml) antiinflammatory intervention Other Name: triamcinolone acetonide, 10mg/ml |
- visual analogue scale for pain (VAS) [ Time Frame: 12 weeks ]
- gait analysis [ Time Frame: 12 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 35 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- men and women between 35 and 80 years of age
- radiographically verified degenerative osteoarthritis of the knee (grade II or III according to the Kellgren and Lawrence classification)
- pain of at least 40 mm on a 100 mm visual analogue scale (VAS) at initial examination
- persisting pain for at least 6 months
- Lequesne-Score of at least 10 points
- good physical and mental status
- good compliance and agreement to participate in this study
Exclusion Criteria:
- non-degeneratively induced osteoarthritis
- rheumatoid arthritis
- ligamentous instability or complete resection of the meniscus
- Sudeck´s disease
- operations of the affected knee within the last three months
- varus or valgus deformity of more than 15 degrees
- patellofemoral arthritis
- intraarticular therapy of the affected joint within the last 6 months with hyaluronan and three months with glucocorticoids
- severe systemic diseases (tumor, exacerbated diabetes mellitus, hyperthyroidism)
- anti-thrombotic medication or regular medication with NSAID/psychiatric pharmaceuticals
- infectious diseases
- alcohol abuse
- drugs
- psychiatric diseases or suicidal tendencies
- involvement in another study
- non-compliance
- acute hemarthrosis or joint effusion
- allergic predisposition
- skin infections or skin diseases around the knee

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00731289
Germany | |
Department of Orthopaedics, Movement Analysis Lab, University Hospital Münster, Germany | |
Muenster, Germany, 48149 |
Study Chair: | Susanne Fuchs-Winkelmann, Prof. MD | University Hospital Marburg |
Responsible Party: | Adrian Skwara, Department of Orthopaedics and Rheumatology, University Hospital Marburg |
ClinicalTrials.gov Identifier: | NCT00731289 |
Other Study ID Numbers: |
3II Fuchs |
First Posted: | August 8, 2008 Key Record Dates |
Last Update Posted: | August 8, 2008 |
Last Verified: | August 2008 |
Osteoarthritis Knee Hyaluronan Gait Analysis |
Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Triamcinolone Triamcinolone Acetonide Triamcinolone hexacetonide Hyaluronic Acid Triamcinolone diacetate Anti-Inflammatory Agents |
Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Immunosuppressive Agents Immunologic Factors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Adjuvants, Immunologic Viscosupplements Protective Agents |